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Abstract Oculopharyngeal muscular dystrophy (OPMD)
is a progressive skeletal muscle dystrophy characterized by
ptosis, dysphagia, and upper and lower extremity weak-
ness. We examined eight genetically confirmed OPMD
patients to detect a MRI pattern and correlate muscle
involvement, with validated clinical evaluation methods.
Physical assessment was performed using the Motor
Function Measurement (MFM) scale. We imaged the lower
extremities on a 1.5 T scanner. Fatty replacement was
graded on a 4-point visual scale. We found prominent
affection of the adductor and hamstring muscles in the
thigh, and soleus and gastrocnemius muscles in the lower
leg. The MFM assessment showed relative mild clinical
impairment, mostly affecting standing and transfers, while
distal motor capacity was hardly affected. We observed a
high (negative) correlation between the validated clinical
scores and our visual imaging scores suggesting that
quantitative and more objective muscle MRI might serve as
outcome measure for clinical trials in muscular
dystrophies.
Keywords MRI  Motor function measurement 
Outcome measure  Muscle  Oculopharyngeal muscular
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Introduction
Oculopharyngeal muscular dystrophy (OPMD) is a rare,
slowly progressive autosomal dominant muscular dystro-
phy, although cases of autosomal recessive inheritance are
reported [1]. Compared to Duchenne or limb girdle muscular
dystrophies (LGMD), disease onset is late adult age with a
mean age of 45 years (range 30–60 years), and disease
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progression in OPMD is relatively slow. It has an estimated
prevalence of 1 in 100,000 worldwide [2], but it is much
more common (1:1,000–1:600) in certain ethnic communi-
ties, such as French Canadians [3] and Bukhara Jews [4].
OPMD is caused by a mutation in the ubiquitously
expressed Polyadenlyate binding protein-1 (PABPN1)-gene
[5]. The clinical phenotype in OPMD, however, is restricted
to skeletal muscles, especially to the cricopharyngeal and
levator palpebrae muscles. The initial symptom in most
cases is a slowly progressing ptosis, while later dysphagia
due to muscular weakness might compromise oral food
intake. Facial weakness and involvement of proximal lower
extremity muscles are described in more advanced stages [6].
Muscular biopsies of OPMD patients showed rimmed
vacuoles and intranuclear inclusions as well as atrophic and
hypertrophic fibers. Predominance of Type 1 fibers is also
common [7]. Diagnosis is usually made clinically and three
criteria are required for a clinical diagnosis of autosomal
dominant OPMD: a positive family history, the presence of
ptosis, and the presence of dysphagia [8]. Definitive diagnosis
depends upon genetic testing for a polyalanin-repeat expan-
sion in the PABPN1-gene and the detection of more than 10
‘‘GCN’’ trinucleotide repeats in the first exon of PABPN1 [9].
The triplet repeat in PABPN1 is stable, and triplet repeat
expansion is uncommon. In contrast to many other triplet
disorders, there is no known clinical anticipation in OPMD.
Recent studies on muscle imaging showed the useful-
ness of pattern recognition for the differential diagnosis of
muscular dystrophies [10, 11]. Previous studies in OPMD
describe proximal weakness and pelvic girdle involvement
[4, 9]. CT and MRI demonstrated fatty replacement of the
shoulder girdle muscles [12, 13]. However, thigh and lower
leg muscle involvement has neither been studied system-
atically, nor compared to clinically validated tests or to the
pattern of involvement in other hereditary myopathies.
The aim of this study was, therefore, to establish a
pattern of muscular involvement in OPMD and to correlate
fatty infiltration to validated clinical tests.
Materials and methods
Patients
Patients with OPMD that had been identified in the
Department of Medical Genetics of the University of Basel
Children’s Hospital were invited to participate in this
study. Eight genetically confirmed OPMD patients agreed
and were recruited (age range 41–76 years, 6 female, 2
male). The youngest patient presented without symptoms
of OPMD. Written informed consent was obtained from all
patients. All measurements were approved by the local
ethics committee (EKBB-Nr. 83/08).
Clinical assessment of muscle weakness
Physical assessment was performed prior to imaging in all
but two patients, who did not wish to participate in this part
of the study. We used the Motor Function Measurement
(MFM) scale, which covers the whole range of abilities in
both ambulant and non-ambulant patients. This scale
comprised items from the following three dimensions:
standing position and transfers, axial and proximal motor
function, distal motor function. Each dimension is evalu-
ated as a subset score, as well as a total score given in
percentage points. It has been shown that this scale has a
high inter-rater reliability, does not require any special
equipment and is well tolerated by patients [14].
Magnetic resonance imaging
All imaging was performed on a 1.5 T whole body scanner
(Magnetom Avanto, Siemens, Erlangen, Germany) with a
dedicated 16-element matrix coil. Patients were placed with
the knee joint in the center of the magnet. To permit
reproduction for future follow-up examinations, two axial
slice groups were placed centered at 14.5 cm below and
17.5 cm above the knee joint respectively, to include the
largest diameter of the thigh and the lower leg. An imaging
matrix of 384 9 384 and a field of view of 400 9 400 mm2
were used, resulting in a 1 mm inplane resolution with
3 mm slice thickness. A T1 weighted turbo spin echo (TSE)
sequence (TR 457 ms, TE 7.5 ms, Turbo factor 5, acqui-
sition time 3:02 min) as well as a T2 weighted multi-con-
trast SE sequence (TR 1,330 ms, TE 10–320 ms, flip
angle = 25, acquisition time 2:23 min) were acquired, and
fat- and water-selective images were calculated to distin-
guish fatty infiltration in T2 from edematous changes.
Image evaluation
Images were digitally displayed on a diagnostic radiologic
workstation with high-resolution monitors. All images
were evaluated by one radiologist with 4 years of postfel-
low experience in neuromuscular imaging, who was blin-
ded to clinical findings. Images were repeatedly evaluated
after at least 1 month to assess intra-reader variability.
Fatty replacement of muscle was graded on a 4-point scale
derived from a scale proposed by Mercuri et al. [15]
(0 = no fatty replacement; 1 = minimal fatty replacement;
2 = moderate fatty replacement less than 50% of muscle
involvement; 3 = extensive fatty replacement of the mus-
cle, more than 50% of muscle involved).
All muscles visible in the field of view were included in
the evaluation, these comprised the thigh: quadriceps
femoris (medial, lateral, intermediate vastus and rectus
femoris), adductor magnus and longus, long and short head
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of the biceps femoris, semimembranosus and semitendino-
sus, gracilis and sartorius. In the lower leg we evaluated:
soleus, medial and lateral part of the gastrocnemius, anterior
and posterior tibial, long peroneal muscle. The flexor hal-
lucis and digitorum longus as well as the extensor hallucis
and digitorum longus, respectively were evaluated as one,
because these muscles could not be reliably separated in MRI
images. Each muscle was assigned a fatty replacement score,
with separate scores for the left and right side.
In addition, the pattern of muscular involvement was
compared to those of different myopathies established in
the literature [10, 15–19].
Statistical analysis
Imaging scores were analyzed on a patient by patient basis
due to symmetrical involvement of the legs. Arithmetic
middle of the scores from the thigh, lower leg and whole
leg were calculated and compared to clinical assessment of
the MFM scale. Correlations of clinical and MRI scores
were calculated as Pearson correlation coefficient with
JMP 8.0.2 (SAS Institute, Cary (NC), USA).
Results
Clinical data
Eight patients with genetically proven OPMD were inclu-
ded into our study.
Seven patients were heterozygous carriers of a (GCN)13
allele resulting in the insertion of 3 additional alanines into the
PABPN1 protein. Patient 3 harboured a (GCN)15 allele leading
to an expansion of the polyalanine tract by 5 amino acids.
Mean age at onset of symptoms was 47 (40–50), average
duration of symptoms was 20 years (10–35). The mean age
at examination was 60 years, the median 62 years. Apart
from patient 6, who was a 41 year old presymptomatic
patient, all other patients had symptoms and clinical
weakness. All had a bilateral ptosis, different degrees of
dysphagia and proximal leg weakness. Details on the
clinical data are provided in Table 1. The total mean MFM
score of all six examined patients was 94.0%. The mean D1
(standing and transfers) subscore was 85.8%; the D2 (axial
and proximal motor capacity) subscore was 96.7%; and the
D3 (distal motor capacity) was 97.8%. D1 was in all but
one patient the lowest subscore, and D3 in all but another
patient the highest subscore.
Muscle imaging findings
All but one patient (patient 6), presented with some degree of
fatty muscular degeneration. Patient 6 only showed minimal
fatty streaks bilaterally in the soleus. All affected patients
displayed a similar pattern of muscular involvement with
symmetric values in 98.5%—6 of 400 muscles evaluated
showed a 1 point difference (Table 2 and additional online
material). At the thigh level fatty replacement was promi-
nent in the adductor magnus and hamstring (semimembr-
anosus, biceps femoris) muscles (Fig. 1). Patients with
involvement of the vastus intermedius muscle showed fatty
replacement mainly in the deeper parts of the muscle next to
the femur (oblique arrows in Fig. 1). The gracilis (large
arrow in Fig. 1) and the vastus medialis muscles were spared
in all patients even in those with the most severe fatty
infiltration. In the lower leg, the muscles of the posterior
compartment were more involved than the muscles of the
relatively spared anterior compartment. The most affected
muscle was the soleus muscle followed by the medial gas-
trocnemius muscle, the lateral gastrocnemius, and peroneal
muscles while the tibialis anterior muscle was relatively
spared (Fig. 2). Similar to the pronounced intramuscular
Table 1 Clinical data of 8 patients with OPMD
Patient Sex Age at
onset/years
Age at
exam/years
Ptosis Dysphagia Weakness MFM total MFM D1 MFM D2 MFM D3
1 F 40 75 BP CPM - 98 100 94 100
2 M 45 69 BP ?? ??? 84 64 97 100
3 F 49 59 ??? ? ?? 97 92 100 97
4 F 55 61 BP ? ?? 92 77 92 100
5 F 50 63 BP ?? ? 93 82 97 90
6 M – 41 – – – 100 100 100 100
7 F – 54 ? – – n.a. n.a. n.a. n.a.
8 F 50 69 BP CPM ? n.a. n.a. n.a. n.a.
Patients 7 and 8 refused MFM measurements, n.a. = not applicable
MFM D1, MFM D2, MFM D3 motor function measurement with subscores in %. CPM cricopharyngeal muscle; BP bilateral ptosis; - no
involvement, ? mild involvement, ?? moderate involvement, ??? strong involvement
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affection of the vastus intermedius muscle, the same char-
acteristic variation was found in the gastrocnemius muscle,
where deeper parts were also more prominently involved
than the superficial parts. Details of muscle involvement
scores of each patient and mean muscle involvement of each
muscle are shown in Table 2. We found no edematous
changes in any of the involved muscles.
Correlation of clinical and MR findings
The duration of symptoms weakly correlated to MRI scores
(R2 = 0.3), while no correlation to MFM was detected.
Especially, patient 1 with a long history since symptom
onset had only minor changes in muscular MRI and in the
MFM scores. As the mutation of this patient was identical
to the other patients, there is currently no explanation for
this phenomenon. However, fatty replacement and extent
of muscle involvement increased with progressive periph-
eral weakness. Linear regression with Pearson’s correlation
coefficient between the MFM scores and the mean muscle
affection score across all muscles as assessed by MRI is
shown in Fig. 3. A strong negative correlation R2 = -0.94
was observed between the total MFM score and the
imaging scores. The analysis of the subscores revealed that
most of the correlation was based on the D1 (standing and
transfers) with an R2 of -0.87 while the D2 (axial and
proximal motor capacity) subscore and the D3 (distal
motor capacity) showed no correlation to muscular fatty
degeneration with R2 of -0.02 and 0.13, respectively.
Separate analysis of MRI for the thigh and lower leg and
correlation to the MFM subscores revealed no additional
negative correlation: the correlation of D1 with MRI
involvement of the thigh muscles improved slightly to
R2 = -0.91, while the correlation of D1 to the involve-
ment of the lower leg showed a non significant R2 =
-0.77. Omission of the patients 6 (who was asymptomatic)
and 1 (who had a different clinical profile) reduced the
level of confidence but had no major influence on corre-
lations (additional online material).
Discussion
In this study we performed a systematic prospective muscle
imaging assessment in eight patients with genetically pro-
ven OPMD.
Table 2 Degree of muscular fatty degeneration on a visual 4-point scale (0–3)
Patient muscle 1 2 3 4 5 6 7 8 Average muscular
fatty
degeneration
Vastus lateralis 0 1 0 0 0 0 1 0 0.25
Vastus intermedius 0 2 0 0 0 0 1 0 0.375
Vastus medialis 0 0 0 0 0 0 0 0 0
Rectus femoris 0 1 0 0 0 0 0 0 0.125
Sartorius 0 0 0 1 0 0 0 1 0.25
Adductor longus 0 3 0 0 0 0 0 0 0.375
Adductor magnus 1 3 2 2 2 0 2* 2 1.75
Gracilis 0 0 0 0 0 0 0 0 0
Semimembranous 1 3 0 1 1 0 2* 2 1.25
Semitendinous 0 3 1 1 1 0 1 1 1
Long biceps 0 3 1 1 1 0 1* 1 1
Short biceps 0 2 0 1 0 0 1* 1 0.625
Anterior tibial 0 0 0 0 0 0 0 0 0
Digital extensor 0 1 0 0 0 0 0 0 0.125
Long peroneal 0 2 0 0 1 0 1* 0 0.5
Posterior tibial 0 0* 0 0 0 0 0 0 0
Digital flexor 0 1 0 0 0 0 0 0 0.125
Soleus 1 3 2 1 2 1 1 1 1.5
Medial gastrocnemius 0 2 1 0 0 0 2 0 0.625
Lateral gastrocnemius 0 1 0 0 0 0 1 0 0.25
Average muscular fatty degeneration 0.14 1.45 0.32 0.36 0.36 0.045 0.64 0.41 0.47
Average thigh 0.17 1.75 0.33 0.58 0.42 0 0.75 0.67 0.48
Average calf 0.1 1.1 0.3 0.1 0.3 0.1 0.5 0.1 0.48
* A small difference between right and left, usually with greater atrophy on the right side (see additional online material)
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While in other myopathies with predominant proximal
weakness (as LGMD) or myopathies with late adult onset
(e.g. myofibrillar myopathies) a typical imaging pattern is
described [18, 19], no such pattern is currently known for
muscle involvement in OPMD. We could detect a char-
acteristic pattern distinct from other known moyopathies as
visualized in Figs. 1 and 2: At the thigh, we found early
and predominant involvement of the adductor magnus,
semimembranosus, and biceps femoris muscles. In more
severely affected patients also the semitendinosus muscle
showed fatty infiltration, while sartorius and gracilis mus-
cles were relatively spared in all patients. In the lower leg,
the posterior compartment muscles showed more fatty
infiltration than the anterior compartment muscles. The
most affected muscle was the soleus muscle followed by
the medial gastrocnemius muscle. In more severely affec-
ted patients also involvement of the lateral gastrocnemius
and peroneal muscles was observed, while the tibialis
anterior muscle was relatively spared. When comparing the
pattern observed in OPMDs to other muscular dystrophies,
predominant medial and posterior thigh and posterior lower
leg involvement is also a typical finding in LGMD2A,
LGMD2B, LGMD2I and Z-disc related myofibrillar
Fig. 1 T1 weighted images of the thigh with fatty replacement and
atrophy in three patients showing different stages of involvement
Bottom to top patient 3 (age 59 years, disease duration 10 years),
patient 4 (age 61 years, disease duration 6 years), patient 2 (age 69
years, disease duration 24 years). Curved arrow lipoma in the right
semimembranosus. VL lateral vastus, VI intermediate vastus, VM
medial vastus, RF rectus femoris, SA sartorius, AL long adductor, AM
major adductor, GR gracilis, SM semimembranosus, ST semitendino-
sus, BL long biceps, BB short
Fig. 2 Muscular MRI (T1 weighted sequences) of the lower leg of
three patients with different stages of involvement from bottom to
top patient 3 (age 59 years, disease duration 10 years), patient 4 (age
61 years, disease duration 6 years), patient 2 (age 69 years, disease
duration 24 years), TA anterior tibial, TP posterior tibial, ED extensor
digitorum, EH extensor hallucis, PL long peroneal, FD digital and
hallux flexor, SO soleus, GM gastrocnemius (medial head), GL
gastrocnemius (lateral head)
J Neurol (2011) 258:1333–1340 1337
123
myopathies related to mutations in the myotilin, filamin-c,
and ZASP genes. Distinction based on clinical findings
between those entities usually is not difficult due to the
pronounced ocular and bulbar affection in OPMD, the
scapular winging often present in LGMD2A and LGMD2I,
and the distal presentation most often found in Z-disc
related myofibrillar myopathies. In addition to these clini-
cal and pathologic findings subtle differences between the
entities on muscle imaging are visible. In patients with
involvement of the vastus intermedius and vastus lateralis
muscles, we found predominant involvement of deep
muscular layers, which has not been observed in myofibr-
illar myopathies [18], and in LGMD2I [18]. Nondystrophic
myopathies on the other hand showed no muscular
involvement despite severe clinical symptoms [20].
The most similar pattern to that observed in OPMD is
the pattern described in LGMD2A [15, 18], where a similar
involvement of the vastus intermedius muscle is found.
Therefore, though the clinical presentation is absolutely
different, a distinction between those two entities based
solely on imaging findings of leg muscles seems hardly
possible. Involvement of the posterior lower leg in
LGMD2B was more prominent in the lateral gastrocnemius
[17], in contrast to OPMD, where the medial head of the
gastrocnemius was more affected than the lateral. In
myotonic dystrophy (DM) type 1 the involvement of deep
parts of the vastus intermedius as well as involvement of
the posterior lower leg is similar to OPMD, while the
hamstring muscles as well as the adductor magnus were
rarely involved, which would facilitate the differentiation
[16] and guide genetic testing, as the clinical presentation
of myotonic dystrophies in early stages can sometimes
resemble OPMD.
All patients in our trial presented with ptosis as initial
symptom, and more variably with dysphagia and proximal
leg muscle weakness. The mean age of onset at 47 in our
study population was similar to other previous reports [8];
while, in contrast to our data, only half of the patients in
France presented with ptosis [4]. Disease duration was
variable (6–35 years) but did not correlate to the degree
of peripheral muscle weakness. This finding is of interest
as in OPMD, age of onset and progression are usually
relatively constant [8]. The lack of correlation between
onset and severity might also be caused by differences in
the awareness of mild disabilities such as a beginning
ptosis. To assess more objectively the clinical and func-
tional impairment, we utilised the MFM, a validated and
reliable clinical score, which covers a broad range of
abilities in ambulant (and non-ambulant) patients. Using
MFM we observed an overall relative mild mean affec-
tion. The subscores, however, showed the most involve-
ment of standing and transfers, and to a lower degree
affection of axial and proximal motor capacity, while
motor abilities of distal muscles were hardly affected.
This clinical pattern is in accordance to previous reports
describing predominant proximal involvement in addition
to the marked oculobulbar weakness [9]. The pattern of
muscular weakness with predominant axial and proximal
muscle involvement was also mirrored in our muscle MRI
analysis.
To quantify the correlation of clinical and imaging data,
fatty replacement scores were aggregated to a mean mus-
cular involvement for the whole lower extremity and into
subscores for the thigh and lower leg. The mean involve-
ment across all muscles of an individual patient provides a
broad impression of the degree of disease severity (Fig. 3).
We could observe a high negative correlation of R2 =
-0.94 between the validated clinical scores and our visual
imaging scores, indicating that an increased fatty degen-
eration of muscles correlates to reduced clinical abilities
and impaired muscular function. While correlation of
overall MFM and D1 subscores (transfer and axial func-
tions) to imaging were strong, we found only a minimal
correlation to the D2 and D3 subscores (proximal and distal
motor functions). This might be due to the fact that the
latter subcategories are evaluated with tasks involving
mainly the upper extremities, and only the lower extremi-
ties were studied in MRI. As category D3 is rather
dependent on fine motor skills than on overall muscle
strength, it is unlikely that the correlation would have
improved, if the upper extremities were to be included in
the imaging evaluation.
Fig. 3 Correlation of MFM-
aggregate values and muscular
fatty replacement on the visual
scale show a high negative
correlation. Left MFM total
score by average muscular
involvement. Right MFM D1
subscore by average muscular
involvement of the thigh
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The strong correlation to clinical affection suggests that
muscular MRI might serve as a surrogate outcome
parameter for clinical involvement in trials of novel ther-
apies which are currently under development. However,
further studies including objective quantitative muscle
MRI data are necessary to confirm and validate this
observation. Potential quantitative methods as reference
standards might include volumetric evaluation of fat per-
centage in musculature, T2 measurements in involved
muscles or spectroscopic analysis of fat content. Future
trials should preferably also include follow up cohorts to
evaluate disease progress over time and correlate deterio-
rating clinical status to increased fatty infiltration on a
single-patient basis.
In this context the findings in the presymptomatic
patient 6 are especially interesting. While the genetic
defect in this patient established the diagnosis, only mini-
mal changes in the soleus muscle were visible. These
changes might represent a precursor of future muscular
involvement. Whether new imaging methods like diffusion
weighted imaging or diffusion tensor imaging would
improve presymptomatic detection remains to be
established.
The major shortcoming of our study is the small number
of patients stemming only from one region. In this context
it would be advantageous to confirm the pattern of
involvement in a different population.
Another limitation is based on the fact that only semi-
quantitative scores of muscular fatty replacement were
used. This score is established for clinical evaluation of
fatty replacement in neuromuscular disorders [15], but
currently there are no published comparisons to different
established scores for fatty replacement [21].
In conclusion, we found a consistent pattern of muscular
involvement in the lower extremities in OPMD. Muscular
involvement and fatty degeneration was most prominent in
the proximal thigh muscles, with prominent affection of the
adductor and hamstring muscles in the thigh, and less
marked soleus and gastrocnemius muscle involvement in
the lower leg. Furthermore, we observed a strong negative
correlation between the validated clinical scores and our
visual imaging scores suggesting that quantitative and
more objective muscle MRI might serve as a potential
biomarker and outcome measure for clinical trials in
muscular dystrophies.
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